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Background: There is no established standard chemotherapy for
patients with locally advanced or metastatic biliary tract cancer.
We initially conducted a randomized, phase 2 study involving 86
patients to compare cisplatin plus gemcitabine with gemcitabine
alone. After we found an improvement in progression-free survival,
the trial was extended to the phase 3 trial reported here.
Methods:We randomly assigned 410 patients with locally advanced
or metastatic cholangiocarcinoma, gallbladder cancer, or ampullary
cancer to receive either cisplatin (25 mg per square meter of body-
surface area) followed by gemcitabine (1000 mg per square meter
on days 1 and 8, every 3 weeks for eight cycles) or gemcitabine alone
(1000 mg per square meter on days 1, 8, and 15, every 4 weeks for
six cycles) for up to 24 weeks. The primary end point was overall
survival.
Results: After a median follow-up of 8.2 months and 327 deaths, the
median overall survival was 11.7 months among the 204 patients in
the cisplatin–gemcitabine group and 8.1 months among the 206
patients in the gemcitabine group (hazard ratio, 0.64; 95% conﬁdence
interval, 0.52–0.80; p <0.001). The median progression-free survival
was 8.0 months in the cisplatin–gemcitabine group and 5.0 months
in the gemcitabine-only group (p <0.001). In addition, the rate of
tumor control among patients in the cisplatin–gemcitabine group
was signiﬁcantly increased (81.4% vs. 71.8%, p = 0.049). Adverse
events were similar in the two groups, with the exception of more
neutropenia in the cisplatin–gemcitabine group; the number of neu-
tropenia-associated infections was similar in the two groups.Journal of Hepatology 20
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Biliary tract cancers (BTC) are a heterogeneous group of carcino-
mas with features of cholangiocyte differentiation originating
from the epithelium of the bile ducts and gallbladder. They can
be classiﬁed into cholangiocarcinoma (CCA; intrahepatic, perihi-
lar, and extrahepatic), gallbladder carcinoma (GBC), and ampul-
lary cancer. Each of these is characterized by distinct clinical
behaviors and genetic signatures. These tumors are highly lethal
due to the advanced stage at diagnosis, poor response to systemic
therapy, and a high rate of recurrence after surgical treatment.
Additionally, there is a trend toward increasing incidence of
BTC, mainly due to an increase of intrahepatic CCA. Over the last
25 years, the ﬁve-year survival rate remains dismal (<10%) [1].
Because of disease heterogeneity, associated cholestatic liver dys-
function and small numbers, BTC have been seldom studied in
clinical trials employing systemic therapy.
Studies evaluating the efﬁcacy of cytotoxic chemotherapeutic
agents for BTC have examined ﬂuorouracil, gemcitabine, cis-
platin, oxaliplatin, and mitomycin C. These studies suggested that
the combination of gemcitabine plus platinum-based agents is
the palliative option with the greatest potential [2]. However,
these studies were underpowered phase 2 trials with limited
evidence favoring one combination over another. Reports on
the tolerability of gemcitabine-based regimens versus solo treat-
ment with gemcitabine described more side effects with the dual
therapy, with up to >50% study withdrawal rate [3]. Establish-
ment of a baseline chemotherapeutic regimen based on well-
powered, randomized-controlled trials was a long-awaited step
for BTC. Toward this goal, Valle and colleagues conducted a
multicenter phase 3 randomized-controlled trial to deﬁne the
efﬁcacy and tolerability of gemcitabine alone versus its combina-
tion with cisplatin for the treatment of locally advanced and met-
astatic BTC (the Advanced Biliary Cancer [ABC]-02) [4]. This trial
was a successful extension of a positive phase 2 trial (the ABC-01)
which used the same eligibility criteria and randomization [5].
The timely transition and identical design of the ABC-01 and
ABC-02 allowed incorporating the data from phase 2 into a phase11 vol. 54 j 577–578
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3 trial, which represents a unique study design. The primary out-
come was overall survival (OS); the secondary outcomes were
progression-free survival (PFS), tumor response, and adverse
effects. Patients with serum liver enzymes P5 times the upper
limit of normal, and/or a serum total bilirubin P1.5 times the
upper limit of normal were excluded from the study.
The study of Valle et al. demonstrated an improvement in OS
in the gemcitabine–cisplatin group as compared to gemcitabine
alone (11.7 months versus 8.1 months, p <0.001). PFS was also
improved in the combination group as compared with the gem-
citabine-only group (8.0 months versus 5.0 months, p <0.001).
The overall risk of dying was 36% less in the gemcitabine–cis-
platin group (hazard ratio 0.64; 95% CI, 0.52–0.80). However,
when the patients’ subgroups were examined, signiﬁcant
response rates were achieved primarily in patients with GBC
and intrahepatic CCA. The conﬁdence intervals for the hazard
ratio for both perihilar and ampullary BTC subgroups crossed
one and did not achieve statistical signiﬁcance. This may be
due to a lack of statistical power for the individual subgroups
(only 20 patients with ampullary carcinoma and 57 with periph-
eral disease) or due to the different biology of these cancers.
The tolerability proﬁle was reported to be similar between
treatment arms, except for the frequency of neutropenia, which
did not translate into an increased rate of neutropenia related
infections. However, keeping in mind that palliative care is
focused on alleviating the severity of symptoms, improving the
quality of life and psychosocial wellbeing, we need to be more
critical and attentive to side-effects inﬂuencing these parameters.
The ABC-01 trial demonstrated a striking prevalence of lethargy
in the combination arm versus gemcitabine alone (28.6% vs
9.1%). Stomatitis, diarrhea, and pain, potentially inﬂuencing qual-
ity of life, also were more prevalent in the combination arm in the
ABC-01. Unfortunately, none of these adverse effects was com-
mented on the ABC-02 trial. A cost-effectiveness analysis is
another essential component in the decision-making process.
Apparently these analyses may be presented in forthcoming pub-
lications, and we await this information.
What can we advise our patients based on the Valle et al.
study? Gemcitabine–cisplatin combination modestly improves
survival in GBC and intrahepatic CCA, though it is not curative,
and there are no data available measuring the quality of life.
Clearly, the survival advantage of the combination is modest,
and continued studies are necessary to eventually cure this
disease. Where do we go from here, especially with less toxic578 Journal of Hepatology 201targeted therapies? Most of our patients have perihilar disease
with serum bilirubin P1.5 times the upper limit of normal,
despite endoscopic placement of biliary stents. We would argue
that for these patients equipoise still exists and trials of a tar-
geted agent versus gemcitabine plus cisplatin would be most
informative. Promising targeted therapies include the epidermal
growth factor receptor (EGFR) inhibitor cetuximab and mito-
gen-activated protein kinase (MEK) inhibitors, for which there
are several in development [6]. For GBC or intrahepatic CCA, gem-
citabine–cisplatin combination will be the standard of care for
eligible patients (nonicteric, performance status 62). Targeted
therapies can be added to this regiment or studied as a second
line therapy. Phase 3 trials should be based on rigorously
designed phase 2 trials utilizing comparator arms [7]. The ABC-
2 success will hopefully encourage further interest in beating this
devastating disease. We still have a long way to go.Conﬂict of interest
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